Member Info for AnthonyW

@Mars £47k award. Wonder how much they are supplying and why. Wouldn't say this is screwing UK LFT

@Benny 100%. Which is why they won't answer that question or report you to LSE in the case of TWATCHER when you ask their target price.

@Gary in all seriousness that's your target?

@Gary what's your target price for ODX?

@Dave what's your target price for GDR?

@Dave to be fair though - Beckman's sister company Cytiva are making the AIHL tests. They all sit under the Danaher umbrella.

Don't engage with them. Filter the following:
Gary
Shelly
Twatcher
Swag

Gsk need something to bolster their sales pipeline in the shorterm. They have the marketing and sales force and more importantly they know governments too

Snoop is also dre trades on twitter if you want a laugh

Not been updated since Mar 3rd....

Scinv- what's your SP target for your "reduced holding"?

We know SNG have amended their protocol to look at this. Hopefully we will have some results from those recruited to the phase 2 last year released soon.

Scinv - lol I think I'm the only one who reads your posts. Have a nice weekend. Try and get some sunshine.

Scinv-Do you ever get the feeling you're talking to just yourself?

Scinv- I think you should write to Numis and other brokers to tell them they have got it all wrong and in fact the company is worthless let alone its current almost 300 million market cap.

Scinv-you're wasted here. I'm sure these big investment groups would reward you for warning them about investing in a company without a justifiable patent. https://tools.morningstar.co.uk/uk/stockreport/default.aspx?tab=5&vw=own&SecurityToken=0P00007OXV%5D3%5D0%5DE0WWE%24%24ALL&Id=0P00007OXV&ClientFund=0&CurrencyId=BAS
Or even the FDA and EMA might appreciate you to warn them they are wasting their time who have them on track to register (upon successful phase 3 trial) for this indication. You should also advise whichever company snaps them up they are wasting their time. You are full of the smelliest brown stuff imaginable. I can see which ever pharma company you claim to work for won't allow you in their medical affairs department.

@Doc-Clinical trials gov website hasn't been updated since March 3rd(SNG don't control this). https://clinicaltrials.gov/ct2/show/NCT04732949?term=sprinter&draw=2&rank=6
It's likely the centres will say recruiting until the trial has recruited fully. The only way someone will know how many patients have been recruited is by speaking to a PI (Dr in charge of recruiting to any given centre) on the trial or the company running the trial for SNG (pharmaxis)

Scinv-Its my pleasure. Glad you finally got to learn something. Have a lovely weekend.

Scinv-Thank you for sharing those papers but they are not directly relevant to covid but talk to autoimmunity in non respiratory conditions. I take it you haven't seen any of Prof Wilkinsons recent lectures or their biobank work or even why IFN beta 1a was chosen ahead of any of the other IFN type 1. You also don't give any reference to rates of auto antibody to IFN beta as I requested. Yes they share the same receptor as IFN alfa but that makes using IFN beta more important as it can fill the receptor while IFN alpha is being blocked by an auto antibody. I give you points for trying but I'll raise your BSc with a PhD and years of pharma experience.

@Scinv "And just to add, in a large study back in october, when they checked the outcomes all cases with autoantibodies had more severe disease, it just that was only a subset of patients with severe disiease so it is not the only determining factor, but it is *definitely* one."
Please provide a link to this study. Also can you show me the break of what % autoantibody are for each IFN subtype. We have seen in the literature that IFN autoantibodies are expressed in COVID for the alpha variety. Happy to be proven otherwise but I prefer a scientific paper please.